← All trials
NCT05044039
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2021
- Primary completion
- Feb 26, 2025
- Completion date
- Feb 26, 2025
- First posted
- Sep 14, 2021
- Last posted
- Sep 14, 2021
- Enrollment
- 43
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Washington University in St. LouisLead sponsor
- Washington University in St. LouisOverall official - principal investigator
- SecuraCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.